Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa

Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa

The pH of urine, the drug's pKa, and the urine flow rate are vital parameters for drug reabsorption and excretion. Urinary pH varies between 4.6 and 8.0 and is influenced by diet, drug intake, and the patient's pathophysiology. It affects a drug's ionization state and reabsorption. For instance, carbohydrate-rich food produces alkaline urine promoting drug excretion, while proteins and certain medications like ascorbic acid lead to acidic urine enhancing reabsorption.
The pKa of a drug,...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pathological complete response following systemic therapy with carboplatin-paclitaxel plus pembrolizumab for initially unresectable mismatch repair-deficient advanced endometrial cancer: two case reports.

Gynecologic oncology reports·2026

Same author

Evaluation of GPT-5 for Esophageal Cancer Staging Using Fluorodeoxyglucose Positron Emission Tomography Maximum-Intensity Projection Images: Comparative Pilot Study.

JMIR cancer·2026

Same author

Emergent splenic embolization for refractory immune thrombocytopenia with critical bleeding: a case report.

AME case reports·2025

Same author

Preclinical pharmacological profiles of vornorexant, a novel potent dual orexin receptor antagonist.

The Journal of pharmacology and experimental therapeutics·2025

Same author

Low serum free IL-18 is a novel potential marker for predicting infectious events in patients at dialysis initiation.

Clinical kidney journal·2025

Same author

Recurrent Stroke Prediction by Applying a Stroke Polygenic Risk Score in the Japanese Population.

Stroke·2025

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

Does a proton pump inhibitor cause hypokalemia?

Yoshitaka Maeda¹, Naoki Kojima, Yuya Araki

¹Division of Nephrology, Department of Internal Medicine, Toride Kyodo General Hospital (JA Toride Medical Center, renamed on April 1, 2011), Japan. yoshimaeda43@yahoo.co.jp

Internal Medicine (Tokyo, Japan)

|May 3, 2011

Summary

Proton pump inhibitors (PPIs) can cause hypokalemia, a condition of low potassium, in susceptible individuals. This occurs due to accelerated potassium excretion, especially in cases of alkalosis or kidney issues.

More Related Videos

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

Related Experiment Videos

Last Updated: Jun 2, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

Area of Science:

Nephrology
Gastroenterology
Pharmacology

Background:

Proton pump inhibitors (PPIs) primarily target gastric acid secretion.
The proton pump H(+),K(+)-ATPase is crucial for kidney function and electrolyte balance.
Understanding PPIs' extra-gastric effects is vital for patient safety.

Observation:

Two elderly women (69 and 80 years old) developed hypokalemia while taking omeprazole.
These patients exhibited decreased serum potassium and increased urinary potassium excretion.
Symptoms resolved with potassium supplementation and omeprazole cessation.

Findings:

Omeprazole use was associated with hypokalemia, independent of hypomagnesemia.
Accelerated urinary potassium excretion contributed to the observed low potassium levels.
PPIs may induce hypokalemia in specific conditions like alkalosis or impaired renal potassium handling.

Implications:

Clinicians should monitor potassium levels in patients using PPIs, especially those with risk factors.
This highlights the potential for PPIs to affect kidney electrolyte homeostasis.
Further research into PPIs' renal effects and mechanisms is warranted.